HYDROGEN PEROXIDE

Clinical trials are studying HYDROGEN PEROXIDE as one of several oral antiseptics in patients with respiratory infections. These trials aim to measure immediate virucidal activity, how long the effect lasts, and changes in saliva virus levels in people with COVID-19, influenza A, or RSV.

Table of Contents

Trial overview

The available trial is a clinical study of HYDROGEN PEROXIDE used as one of several oral antiseptics for people with respiratory infections.[1] The study is looking at the immediate virucidal activity in saliva after a single mouth rinse and how long that effect lasts, up to 7 hours after use.[1]

Who can participate

This study includes patients diagnosed with COVID-19, influenza A, or RSV.[1] These conditions are grouped in the trial as respiratory diseases, which means illnesses that affect breathing and the airways.[1]

The trial does not provide more detailed entry rules in the source data, so the main known target group is people already diagnosed with one of these respiratory infections.[1]

What is being measured

The main outcome is viral load in saliva samples taken at different times after the mouthwashes are used.[1] Viral load means the amount of virus found in the sample.[1]

The study also measures the D/T ratio, which is described as a way to estimate the proportion of intact viral particles.[1] In simple terms, this helps researchers estimate how much virus remains whole after treatment.[1]

Researchers are checking these outcomes at different time points after application, including the period up to 7 hours later.[1]

Trial design and phase

This is an interventional study, which means the research team gives a treatment and then measures the results.[1] The trial is in Phase 3, which is a later stage that usually studies a treatment in a larger group of people.[1]

The planned enrollment is 810 participants, showing that this is a fairly large study.[1] The trial status is Authorised.[1]

What the study may help show

This trial is designed to see whether HYDROGEN PEROXIDE, used in the mouth, can quickly reduce virus levels in saliva in people with common respiratory infections.[1] It also aims to show how long any effect lasts after one rinse.[1]

Because the study compares different oral antiseptics, it may help researchers understand which rinse has the strongest immediate effect against respiratory viruses in the mouth.[1]

Trial ID Phase Condition studied Status Enrollment
2024-515939-30-01 Phase 3 Respiratory diseases; COVID-19, influenza A, RSV Authorised 810

Ongoing Clinical Trials on HYDROGEN PEROXIDE

  • Phase II Study of Intratumoral Hydrogen Peroxide (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study on the Effect of Povidone-Iodine, Hydrogen Peroxide, and Water for Injection on COVID-19, Influenza A, and RSV in Patients

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Spain

Glossary

  • Virucidal activity: How well a treatment can reduce or inactivate viruses.
  • Oral antiseptic: A mouth treatment used in the mouth to help lower germs, including viruses.
  • Respiratory virus: A virus that affects the breathing system, such as COVID-19, influenza A, or RSV.
  • Salivary samples: Samples of spit collected from the mouth for testing.
  • Viral load: The amount of virus found in a sample.
  • D/T ratio: A study measure that compares different virus-related signals to estimate how many virus particles are intact.
  • Intact viral particles: Virus particles that are still whole and may still be active.
  • Phase 3: A later stage of a clinical trial that studies a treatment in a larger group of people.
  • Interventional study: A study where researchers give a treatment or intervention and then measure the results.
  • Enrollment: The number of people planned to join the study.

References

  1. https://clinicaltrials.gov/study/2024-515939-30-01